Anti-PD-1 therapy! GlaxoSmithKline's treatment of mismatch repair defects (dMMR) solid tumors is strong: total remission rate 36-43%!

JANUARY 16, 2021 // -- GlaxoSmithKline (GSK) recently released the latest data on the anti-PD-1 therapy dostarlimab (formerly TSR-042) GARNET Research Queue F at the 2021 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI).
the society assessed the efficacy and safety of dostarimab treatment mismatch repair defects (dMMR) non-endometrial advanced solid tumors.
results showed that the objective remission rate (ORR) of dostarlimab therapy was 38.7% (N-106,95% CI: 29.4-48.6).
addition, after 12.4 months of medium follow-up, the medium remission duration (DOR) was not yet reached, showing lasting remission in various types of tumors.
need to be noted that patients in the GARNET study F queue were dMMR solid tumors that progressed after receiving standard treatment, and there were few treatment options.
data show that dostarimab has the potential to be an important new treatment option for these patients.
dostarlimab is a research humanized anti-PD-1 monoclonal antibody that binds to PD-1 binds and blocks its interaction with liants PD-L1 and PD-L2.
currently, dostarimab is being reviewed by the FDA and the European Union EMA for the treatment of patients with relapsed or advanced dMMR/microsatellite high instability (MSI-H) endometrial cancer who progress during or after platinum-containing chemotherapy.
data from the GARNET study show that dostarimab treated dMMR/MSI-H endometrial cancer with ORR of 42% (95% CI: 31-55) and disease control rate (DCR) of 58% (95% CI:45-69).
, 13 percent of patients were in complete remission (PR) and 30 percent were partially in remission (PR).
at the data cut-off, the mid-level follow-up time was 11.2 months, and the mid-DOR had not yet reached (1.87 to 19.61 plus months).
Axel Hoos, Senior Vice President and Head of Oncology Research and Development at GSK, said, "We are committed to finding new ways to improve the prognostics of patients with difficult cancers who currently have limited treatment options.
these latest results from the ongoing GARNET study show that dostarimab has the potential to help a wide range of patients with solid tumors with DNA mismatch repair defects.
" Photo Source: Team F of the GSKGARNET study included dMMR non-endometrial solid cancer patients, most of whom were gastrointestinal tumors (colorectal cancer, stomach cancer, and small intestine tumors).
of these patients, the majority of patients (n-81) have received two or more systemic treatments.
study, patients received 500 mg dose of dostarlimab every 3 weeks, followed by 1000 mg dose of dostarlimab every 6 weeks until 2 years until the disease progressed or stopped.
objective of the study was to assess objective mitigation rate (ORR) and mitigation duration (DoR) based on RECIST V1.1 through an independent centre review of blind law.
results showed consistent ORR in colorectal cancer patients (n-69) and non-colorectal cancer patients (n-37, including small intestine, stomach, pancreatic, ovarian, liver, and other types of solid cancer).
in patients with colorectal cancer, the ORR was 36.2% (95% CI; 25.0-48.7) and in non-colorectal cancer patients, the ORR was 43.2% (95% CI; 27.1-60.5).
8 per cent of patients in queue F received complete remission.
patients treated with one or more doses of dostarlimab and assessed for safety (n-144), dostarlimab was well-to-do and had a low suspension rate (3.5%) due to treatment-related adverse events (TRAE).
most common TRAEs were fatigue (13%), diarrhea (13%), itching (13%), joint pain (9%) and fatigue (9%).
8% of patients have LEVEL 3 or above TRAE.
deaths associated with dostarlimab were not reported in the study.
() Original origin: GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solids cancers at ASCO Gastrointestinal Cancers Symposium